G
Guardian Therapeutics
Guardian Therapeutics is a well-capitalized, privately owned drug discovery & development venture
About Guardian Therapeutics
Guardian Therapeutics was founded by James C. Gilbert and Shuhao Zhu, two visionaries in the field of biotechnology. With a shared passion for advancing medical science, they established the company with the goal of developing innovative therapeutics using nucleic acids that bind to specific target molecules. This approach aimed to address unmet medical needs and improve patient outcomes.
Under the leadership of Jim Gilbert, who brought nearly 30 years of industry experience from companies like Bayer and Boehringer Ingelheim, Guardian Therapeutics focused on drug discovery and development. The company quickly gained recognition for its cutting-edge research and development capabilities.
Despite being a privately owned venture, Guardian Therapeutics has been well-capitalized, allowing it to pursue its ambitious research agenda without the immediate pressures of public market demands. This financial stability has been crucial in enabling the company to focus on long-term goals and innovation.
While Guardian Therapeutics has not yet undergone an acquisition or IPO, its strategic focus and robust funding position it well for future growth opportunities. The company continues to explore potential partnerships and collaborations to expand its impact in the biotech industry.
Guardian Therapeutics stands as a testament to the power of scientific innovation and the dedication of its founders to improving healthcare through novel therapeutic solutions.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Aug 2018 | $20M | $80M | Undisclosed | — |
Growth signals
Latest recorded traffic for Guardian Therapeutics is 43K monthly website visits, up 38.7% over the last three months. Guardian Therapeutics's team grew 5.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Guardian Therapeutics in the Cambridge ecosystem
The Guardian Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Guardian Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Guardian Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









